close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

3.150 -0.230 (-6.81%)
Streaming Delayed Price Updated: 1:45 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,025
Open 3.310
Bid (Size) 3.050 (100)
Ask (Size) 3.140 (100)
Prev. Close 3.380
Today's Range 3.050 - 3.310
52wk Range 1.327 - 5.480
Shares Outstanding 45,484,310
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance

Performance

YTD
-34.4%
-34.4%
1 Month
-14.9%
-14.9%
3 Month
-13.9%
-13.9%
6 Month
-33.1%
-33.1%
1 Year
+111.4%
+111.4%

More News

Read More
News headline image
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Earnings Preview ↗
Via Benzinga
News headline image
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Financial Results for the First Quarter 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report First Quarter Financial Results on May 11, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
From Cellectis Inc.
Via GlobeNewswire
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Via The Motley Fool
News headline image
Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Announces 2026 Strategy and Catalysts
From Cellectis Inc.
Via GlobeNewswire
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cellectis Announces Arbitral Decision in Dispute with Servier
From Cellectis Inc.
Via GlobeNewswire
News headline image
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
From Cellectis Inc.
Via GlobeNewswire
News headline image
Why Cellectis Stock Is Trading Higher Today ↗
Via Benzinga
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
From Cellectis Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 7, 2025 ↗
Via Benzinga
News headline image
Cellectis to Present a Development Update for eti-cel at ASH 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Cellectis to Report Third Quarter Financial Results on November 7, 2025
From Cellectis Inc.
Via GlobeNewswire
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
From Cellectis Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cellectis S.A. - American Depositary Shares publicly traded?
Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
What exchange does Cellectis S.A. - American Depositary Shares trade on?
Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
What is the current price of Cellectis S.A. - American Depositary Shares?
The current price of Cellectis S.A. - American Depositary Shares is 3.150
When was Cellectis S.A. - American Depositary Shares last traded?
The last trade of Cellectis S.A. - American Depositary Shares was at 06/03/26 01:45 PM ET
What is the market capitalization of Cellectis S.A. - American Depositary Shares?
The market capitalization of Cellectis S.A. - American Depositary Shares is 143.27M
How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
Cellectis S.A. - American Depositary Shares has 143M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today